Study guide

Drusen, geographic atrophy and neovascular phenotypes

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Drusen, geographic atrophy and neovascular phenotypes

Key Takeaways Explain This Topic AI

Different drusen types and RPE changes have different prognostic implications.

US geographic-atrophy approvals must not be presented as equivalent EU availability.

Neovascular lesion classification and multimodal imaging guide assessment of fluid and complications.

Last updated: October 2026

Morphologic Classification of Drusen

Drusen represent focal accumulations of acellular extracellular material located beneath the neurosensory retina, historically localized between the basement membrane of the RPE and the inner collagenous zone of Bruch membrane (sub-RPE deposits):

1. Hard Drusen

Small ( < 63 μ m <63\,\mu\text{m} < 63 μ m in diameter), discrete, nodular, round lesions with crisp, well-demarcated margins.

Represent compact, dense hyaline lipid-protein deposits.

Found universally in the aging population; asymptomatic and carry a minimal standalone risk of progression to choroidal neovascularisation unless accompanied by large confluent drusen.

2. Soft Drusen

Large (typically ≥ 125 μ m \ge 125\,\mu\text{m} ≥ 125 μ m ), pale yellow-white, dome-shaped mounds with indistinct, hazy, confluent boundaries.

Reflect localized dome-like elevations where continuous sheets of neutral lipid and vesicular membranous debris detach the RPE from Bruch membrane (basal linear deposits).

Tend to coalesce over time, forming large drusenoid pigment epithelial detachments (drusenoid PEDs).

Represent the single most important clinical risk factor for progression to geographic atrophy and neovascular AMD.

3. Cuticular Drusen (Basal Laminar Drusen)

Plentiful, tiny ( 25 − 75 μ m 25-75\,\mu\text{m} 25 − 75 μ m ), uniform, triangular or nodular sub-RPE excrescences composed of packed basement membrane collagen.

On funduscopy, they appear as a dense "carpet" of yellow punctate lesions across the macula.

Angiographic Hallmark: On fluorescein angiography (FA), cuticular drusen produce a characteristic "stars in the sky" (or "milky way" ) appearance, demonstrating early, crisp punctate hyperfluorescent transmission window defects that persist into late frames without significant dye leakage.

Complication: Predisposed to developing vitelliform-like exudative macular detachments in middle age.

4. Reticular Pseudodrusen (Subretinal Drusenoid Debris - SDD)

Unlike conventional drusen which accumulate underneath the RPE, reticular pseudodrusen accumulate above the RPE in the subretinal space , between the apical RPE membrane and the photoreceptor inner/outer segment junctions.

Imaging Characteristics: Often difficult to distinguish on standard colour fundus photography, appearing as a subtle, interlacing, ribbon-like yellowish network in the superior macula. They are visualised with exquisite sensitivity on near-infrared reflectance (NIR) (appearing as hyporeflective grouped spots surrounded by hyperreflective halos), blue light fundus autofluorescence (FAF) , and cross-sectional SD-OCT (conical mounds of hyperreflective debris breaching the ellipsoid zone).

Prognostic Significance: Reticular pseudodrusen represent a potent, independent risk factor for rapid progression to geographic atrophy and the development of Type 3 macular neovascularisation (RAP) .

Geographic Atrophy and Complement Inhibitors

Geographic atrophy is advanced non-neovascular AMD with loss of outer retina and RPE. OCT demonstrates loss of outer-retinal structures and hypertransmission; autofluorescence helps map lesion extent. Record foveal involvement, progression and functional difficulties. Care includes smoking cessation, visual rehabilitation, counselling, and surveillance for neovascular conversion; supplements do not regenerate an atrophic fovea.

Pegcetacoplan inhibits C3 and avacincaptad pegol inhibits C5. Their trials measured slowing of lesion growth rather than recovery of lost vision. Risks include repeated-injection complications and neovascular conversion; inflammation/vasculitis concerns differ between products. Trial efficacy does not itself confer authorisation.

For the European context, EMA confirmed refusal of Syfovre (pegcetacoplan) on 19 September 2024 and the Commission refused authorisation on 16 December 2024. The Izelvay (avacincaptad pegol) application was withdrawn on 24 October 2024. US brand approval should not be described as routine EU availability. See EMA Syfovre and EMA Izelvay . Regulatory status should be rechecked before clinical use.

Neovascular AMD (nAMD): Classification & Multimodal Phenotypes

Neovascular (exudative or "wet") AMD is characterized by the pathologic sprouting of fragile, immature capillary networks from the choroid or retina that breach normal anatomic barriers, accompanied by vascular hyperpermeability, lipid exudation, and subretinal haemorrhage. Modern classification divides macular neovascularisation (MNV) into four distinct entities:

1. Type 1 MNV (Occult Neovascularisation)

Anatomic Location: The neovascular complex originates from the choriocapillaris and proliferates strictly underneath the retinal pigment epithelium (sub-RPE space), above Bruch membrane and below the RPE.

Morphology: Commonly presents as a fibrovascular pigment epithelial detachment (fibrovascular PED) or shallow irregular PED on SD-OCT (the "double-layer sign").

Fluorescein Angiography (FA): Lacks early, crisp vascular borders. Appears as stippled, mottled hyperfluorescence in the mid-transit phase with irregular, late-phase pin-point staining or poorly demarcated sub-RPE dye pooling ("leakage of undetermined source").

2. Type 2 MNV (Classic Neovascularisation)

Anatomic Location: The neovascular fronds penetrate through Bruch membrane AND the RPE layer, arborizing within the subretinal space (above the RPE, beneath the neurosensory retina).

Morphology: Presents on SD-OCT as a hyperreflective, well-demarcated subretinal mass resting on the apical surface of an intact or disrupted RPE band, accompanied by adjacent subretinal and intraretinal fluid.

Fluorescein Angiography (FA): Exhibits classic early, bright, lacy, cartwheel-pattern hyperfluorescence with well-delineated margins, followed in late phases by profuse, diffuse dye extravasation that completely obscures the lesion boundaries.

3. Type 3 MNV (Retinal Angiomatous Proliferation - RAP)

Anatomic Location: Angiogenesis originates within the deep capillary plexus of the neurosensory retina (intraretinal neovascularisation), subsequently growing downward into the subretinal space to establish chorio-retinal anastomoses.

Morphology: Clinically presents with superficial intraretinal flame/blot haemorrhages, localized cystoid macular oedema, and a high association with reticular pseudodrusen in elderly Caucasian females. Frequently advances through three stages: Stage 1 (intraretinal), Stage 2 (subretinal extension), and Stage 3 (choroidal anastomosis with vascularised PED). Rapidly bilateral in > 50 % >50\% > 50% of patients within 3 years.

4. Polypoidal Choroidal Vasculopathy (PCV)

Anatomic Location: Considered an aneurysmal variant of Type 1 MNV or a primary manifestation of the pachychoroid disease spectrum . Originates in the inner choroidal vasculature.

characteristic Features: Characterized by an extensive branching vascular network (BVN) terminating in orange-red, nodular, aneurysmal polypoidal vascular ectasias .

Clinical Presentation: Characteristically affects younger patients, men, and individuals of East Asian and African ancestry. Presents with recurrent, massive subretinal haemorrhages, vitreous haemorrhage, and large serosanguineous PEDs with relatively preserved visual acuity in early stages.

Diagnostic Imaging: Indocyanine green angiography (ICGA) is the reference method for demonstrating aneurysmal lesions and the branching network, with early nodular hypercyanescence and sometimes a hypofluorescent halo. OCT features such as sharp-peaked PEDs and sub-RPE ring-like lesions can support a clinical diagnosis when ICGA is unavailable. Integrate the imaging and haemorrhagic phenotype when planning anti-VEGF therapy and selected PDT.